Related Experiment Video
Updated: Aug 13, 2026

13:27
Generation of Human CD40-activated B cells
Published on: October 16, 2009
14.8K
Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
Lee P Richman1, Robert H Vonderheide1
1Abramson Family Cancer Research Institute; Perelman School of Medicine; University of Pennsylvania; Philadelphia, PA USA.
Oncoimmunology
|August 7, 2014
Abstract:
Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast, we have reported that clinically active anti-human CD40 mAb CP-870,893 does not require FcR crosslinking, a finding with translational implications.

